Study summary

The FDA approved sparsentan as the first drug specifically for FSGS

Sparsentan FDA approval for FSGS · Regulatory · Approved April 2026

What was tested

The FDA's review of sparsentan (Filspari) to reduce proteinuria in FSGS, after a 3-month extension.

What they found

What it means

Gives FSGS its first approved targeted treatment; sparsentan was already approved for IgA nephropathy.

Drug Topics ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.